Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study

Independent Validation of the International Grading System for Medullary Thyroid Carcinoma – A single institutional experience

(2023) Daniel J. Lubin et al.   MODERN PATHOLOGY

Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor Samples

(2022) Emanuela Minna et al.   Cancers

Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations

(2021) Justine A. Barletta et al.   ENDOCRINE PATHOLOGY

Evaluation of Grade in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinoma

(2021) Fedaa Najdawi et al.   HISTOPATHOLOGY

International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma

(2021) Bin Xu et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making

(2021) Mary Jane Lim-Fat et al.   NEURO-ONCOLOGY

A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis

(2020) Talia L. Fuchs et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome

(2020) Bayan Alzumaili et al.   MODERN PATHOLOGY

Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel

(2020) Dario de Biase et al.   Diagnostics

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

(2020) Lori J. Wirth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term follow-up of RET Y791F carriers in Denmark 1994-2017: A National Cohort Study

(2019) Sanne Høxbroe Michaelsen et al.   JOURNAL OF SURGICAL ONCOLOGY

Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study

(2019) Rui M B Maciel et al.   Endocrine Connections

The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review

(2019) Jonathan Mark Fussey et al.   CLINICAL ENDOCRINOLOGY

Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations

(2019) Rossella Elisei et al.   Genes

Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis

(2018) Huy Gia Vuong et al.   ENDOCRINE-RELATED CANCER

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with doubleRETmutations

(2016) Cristina Romei et al.   JOURNAL OF MEDICAL GENETICS

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma

(2016) Andreas M. Heilmann et al.   ONCOLOGY

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

(2015) Samuel A. Wells et al.   THYROID

Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making

(2015) Glen Weiss et al.   OncoTargets and Therapy

Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility

(2014) Rodrigo A Toledo et al.   ENDOCRINE-RELATED CANCER

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas

(2014) Michele Simbolo et al.   VIRCHOWS ARCHIV

Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer

(2013) Mingzhao Xing et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon

(2012) A. Boichard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations inRETandRAS

(2012) Nishant Agrawal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer

(2012) Cristina Romei et al.   THYROID

Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series

(2012) Raffaele Ciampi et al.   THYROID

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification

(2011) Caterina Mian et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

(2009) M M Moura et al.   BRITISH JOURNAL OF CANCER

Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study

(2007) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM